Pre-made Omburtamab biosimilar ( Whole mAb Radiolabelled, anti-CD276 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-399
Anti-CD276 therapeutic antibody (Pre-made Omburtamab biosimilar,Whole mAb Radiolabelled) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Omburtamab (formerly burtomab) is a theranostic monoclonal antibody 8H9, conjugated to to 131 iodine, being developed by Y-mAbs Therapeutics, under a license from Memorial Sloan-Kettering Cancer Center, for the diagnosis and treatment of cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD276 therapeutic antibody (Pre-made Omburtamab biosimilar,Whole mAb Radiolabelled)|
|Format||Whole mAb Radiolabelled|
|Highest_Clin_Trial (Jan '20)||Phase-II/III|
|100% SI Structure||5cma:BA|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics|
|Conditions Active||Neuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma;Peritoneal cancer|
|Conditions Discontinued||Solid tumours|